TRANSCENTA-B (06628) announces annual performance, with a net loss of 204 million yuan for the year, a year-on-year decrease of 29.82%.

07:58 31/03/2026

Chuangsheng Group-B (06628) announced its annual performance for the year ending December 31, 2025. The group achieved revenue of 7.435 million yuan during the period, a decrease of 33.98% year-on-year; with a net loss of 204 million yuan for the year, narrowing by 29.82% compared to the previous year; and a basic loss per share of 0.49 yuan.

TRANSCENTA-B (06628) released its annual performance for the year ending December 31, 2025. The group's revenue for the period was 7.435 million yuan, a decrease of 33.98% year-on-year. The group incurred a loss of 204 million yuan during the year, a decrease of 29.82% compared to the previous year. Basic loss per share was 0.49 yuan.

China Glass (03300) announced a net loss attributable to equity shareholders of approximately RMB 4.893 billion in 2025, representing an increase of about 4.58 times year-on-year.

CITIC SEC: The value of energy security is highlighted, and public utilities are expected to benefit from reevaluation

SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.

China Glass (03300) announced a net loss attributable to equity shareholders of approximately RMB 4.893 billion in 2025, representing an increase of about 4.58 times year-on-year.

CITIC SEC: The value of energy security is highlighted, and public utilities are expected to benefit from reevaluation

SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.